Cerebrospinal fluid u-plasminogen activator and matrix metalloproteinase-9 levels in human eosinophilic meningitis associated with angiostrongyliasis.
Cerebrospinal fluid (CSF) urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) levels were measured in patients with eosinophilic meningitis associated with angiostrongyliasis (EOMA) by quantitative sandwich enzyme immunoassays. The CSF concentrations of uPA and MMP-9 were evaluated in 30 EOMA patients and 10 controls. The CSF uPA and MMP-9 levels of the EOMA patients were significantly higher than those of the controls (p<0.001). The positive detection values were 73% (22/30) and 86.7% (26/30) for uPA and MMP-9, respectively. The uPA detection was in correlation with headache duration (p=0.008) and stiff neck (p=0.048), while the MMP-9 was in correlation with CSF total protein (p=0.006), CSF leukocytosis (p=0.004) and CSF eosinophil numbers (p=0.02). CSF uPA and MMP-9 levels are potentially useful for the understanding of immunologic pathogenesis, for therapeutic targets, for the diagnosis of EOMA and for monitoring treatment efficacy.
Sanpool
Oranuch
O
Faculty of Medicine and Research and Diagnostic Center for Emerging Infectious Diseases, Khon Kaen University, Khon Kaen 40002, Thailand.
Intapan
Pewpan M
PM
Thanchomnang
Tongjit
T
Santivarangkana
Taweesak
T
Niwattayakul
Kanigar
K
Chotmongkol
Verajit
V
Maleewong
Wanchai
W
D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D004804:Eosinophils / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000134:cerebrospinal fluid*; D008581:Meningitis / Q000134:cerebrospinal fluid* / Q000150:complications* / Q000201:enzymology; D008875:Middle Aged; D017206:Strongylida Infections / Q000134:cerebrospinal fluid* / Q000150:complications* / Q000201:enzymology; D014568:Urokinase-Type Plasminogen Activator / Q000134:cerebrospinal fluid*; D055815:Young Adult
D014568:Urokinase-Type Plasminogen Activator; D020780:Matrix Metalloproteinase 9